TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04217512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole low dose
Description: Pantoprazole 0.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole high dose
Description: Pantoprazole 1.6 mg\\kg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hydration
Description: Standard hydration alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hydration
Description: Standard hydration alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard hydration
Description: Standard hydration alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin
Study: NCT03535558

Intervention type: DRUG
Intervention: Fluoroquinolone (FQ)
Description: Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.

Intervention type: DRUG
Intervention: Fluoroquinolone (FQ)
Description: Participants exposed to an oral FQ will be observed. The oral FQ included are Levofloxacin, Ciprofloxacin, Moxifloxacin, Ofloxacin, Gemifloxacin. Participants will not receive any intervention as a part of this study.

Intervention type: DRUG
Intervention: Azithromycin (AZ)
Description: Participants exposed to an oral AZ will be observed. Participants will not receive any intervention as a part of this study.

Intervention type: DRUG
Intervention: Sulfamethoxazole/Trimethoprim (ST) Fixed Dose Combination
Description: Participants exposed to an oral ST will be observed. Participants will not receive any intervention as a part of this study.
Study: NCT00171184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily with sham titration
Study: NCT01117519

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion Therapy
Description: Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infusion Therapy
Description: Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
Study: NCT03484065

Intervention type: OTHER
Intervention: Questionnaire quality of life
Study: NCT03950778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human albumin
Description: Patients are divided into 2 groups by envelope randomization. In the treated group, albumin supplementation occurs up to a target of 30 g / l at the end of the test period at a maximum dose of 3 x 100 ml, and no albumin is added above the control value of 20 g / l. Patients with albumin below 20 g / l in the control group are excluded from the study and albumin supplemented. Blood samples are taken directly at the intensive care class, and at the same time on the following days. Urine was collected for 24 hours. The kinetics of the parameters are examined for five days.
Study: NCT02147678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.
Study: NCT02177383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid diet supplementation
Description: Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.~One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells.
Study: NCT00934089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04217329
Description: Topical ocular solution, once-daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: latanoprost vehicle
Description: Topical ocular solution, once-daily for 14 days
Study: NCT01846702

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given as a SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3084077
Description: Given as a SC injection.
Study: NCT03537638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Intervention to rheumatologist and internist responsible for the care of patients with SLE. Implementation multicomponent intervention consisting of: educational component, a computerized clinical decision support system developed from the clinical practice guide - SLE and automated feedback integrated into the electronic medical record system.
Study: NCT02914938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-401
Description: 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV infusion 375 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 80 and 160 mg bid
Study: NCT03567707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-section -Vaginal seeding
Description: Mother-infant pair randomized to vaginal microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the vaginal microbiota soaked gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds. Infants will only undergo the seeding.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-section - Placebo Seeding
Description: Mother-infant pair randomized to placebo microbiota intervention. As soon as the infant is delivered, the infant will be brought to the neonate lamp, and unless the obstetrician or pediatric staff believes it is not in the best interest of the infant, s/he will be swabbed with the placebo gauze. Swabbing will take place ideally within 1 minute after delivery (but no longer than 5 minutes). The swabbing should take approximately 15 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: Mother-infant pair where mother undergoes spontaneous vaginal delivery, with both receiving standard of care.
Study: NCT01391819

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
Study: NCT03946826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Halometasone Cream
Description: Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Halometasone Cream
Description: Halometasone is a potent halogen - containing topical glucocorticoid. Have stronger fight inflammation, fight allergy, contractive hemal, reduce hemal to connect the action of permeability and fight hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaseline
Description: Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Vaseline belongs to a kind of mineral wax, without irritant, not easy to deteriorate, can let skin surface form a protective film when used on the skin, let the moisture of the skin be evaporated not easily, have better protect wet effect

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Description: Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis,is effective in the treatment of psoriasis
Study: NCT00502320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: one 8 mg tablet at bed for up to 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one tablet at bedtime for up to 4 months
Study: NCT02680405

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
Study: NCT05112614

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool samples

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records
Study: NCT03929913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmural Systems Transcatheter Mitral Cerclage Annuloplasty (TMCA)
Description: The Transcatheter Mitral Cerclage Annuloplasty implant has two components, with or without a coronary artery protection element, and the wishbone lock with coronary sinus and right ventricular outflow track limbs. Procedure is performed from a trans-jugular venous approach. Coronary guidewires and microcatheters are used to navigate into a coronary vein to the target capture catheter. The implant is then attached to the back end of the guidewire and pulled out of the internal jugular sheath. The position of the implant is adjusted so the coronary protection element lies directly over any underlying branch of the left coronary artery. The wishbone lock is advanced over the two limbs of the implant and the desired tension is titrated to the degree of mitral regurgitation. Coronary angiography is performed to confirm there is no coronary compression. After desired tension has been achieved, the wishbone lock is locked and the two limbs of the implant are cut with a cutter catheter.
Study: NCT05212428

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva, blood, urine and stool samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive genetic counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete family history

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01708044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate
Study: NCT02147678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2\~0.4 μg/kg/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
Study: NCT01708044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide acetate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT01468545

Intervention type: OTHER
Intervention: Iloprost (Ventavis inhaled, BAYQ6256)
Description: An extra educational reinforcement at baseline and at 6 months will be given to a group of patients

Intervention type: OTHER
Intervention: Iloprost (Ventavis inhaled, BAYQ6256)
Description: No extra educational reinforcement.
Study: NCT02004301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled T4 Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabelled T6 Tablet
Study: NCT03332147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study: NCT02147678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction
Description: For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
Study: NCT03264443

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined training
Description: Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
Study: NCT01538914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block
Description: Postoperative pain is controlled with local analgesics via PVB.
Study: NCT02680405

Intervention type: PROCEDURE
Intervention: Skin tape stripping
Description: Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.

Intervention type: PROCEDURE
Intervention: Skin tape stripping
Description: Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
Study: NCT01681576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 320mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan 320mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 400mg tablet once daily
Study: NCT02271867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: An ultrasound guided ISB was performed with injection aimed to block the C5-root

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: An ultrasound guided ISB was performed with injection aimed to block the C5-root

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block
Description: An ultrasound guided ISB was performed with injection aimed to block the C5-root
Study: NCT01928485

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active surveillance
Description: Undergo active surveillance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunphenon
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01538914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCA
Description: Postoperative pain is controlled with intravenous PCA.
Study: NCT00957411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study: NCT01928485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02494739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt enriched with polyphenols
Description: Yogurt enriched with polyphenols extracted from grape seeds

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yogurt not enriched with polyphenols
Description: Yogurt not enriched with polyphenols
Study: NCT04060576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling treatment with a thinner needle
Description: We will make an application with the dry needling technique with a fine needle on the myofascial trigger points of the gastrocnemius muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling treatment with a medium-sized needle
Description: We will make an application with the dry needling technique with a medium-sized needle on the myofascial trigger points of the gastrocnemius muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling treatment with a thickest needle
Description: We will make an application with the dry needling technique with the thickest needle on the myofascial trigger points of the gastrocnemius muscle.
Study: NCT04447703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Attend Interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Based Intervention
Description: Use web-based genetic education tool online

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary Studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Receive in-person, telehealth, or over-the-phone genetic counseling

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary Studies
Study: NCT00957411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT00099086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Study: NCT04447703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive in-person, telehealth, or over-the-phone genetic counseling
Study: NCT00099086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRh analog
Description: A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)~Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
Study: NCT04447703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use web-based genetic education tool online
Study: NCT02622672

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: water-soluble ubiquinol
Description: 100 mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: glycerin.soy-lecithin, and water
Study: NCT01906788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether Lumefantrine
Study: NCT04447703

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary Studies
Study: NCT03353454

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to maralixibat orally twice daily for 26 weeks.